Foghorn Therapeutics
Jozlyn Clasman is a Senior Scientist in Drug Discovery at Foghorn Therapeutics Inc. since March 2022, previously serving as a Scientist in Structural Biology. Prior experience includes roles at Agios Pharmaceuticals as an Associate Scientist and Contract Scientist, as well as a Postdoctoral Associate at Boston University in Prof Karen Allen's lab, where Jozlyn focused on membrane-associated proteins for antibacterial drug discovery. Academic training includes a Ph.D. in Biomolecular Structure and Biophysics from Purdue University, where research involved substrate specificity of coronavirus proteases, and a B.S. in Chemistry from Grand Valley State University, where initial research centered on the mechanisms of β-lactamases.
This person is not in any teams
This person is not in any offices
Foghorn Therapeutics
1 followers
Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Their proprietary Gene Traffic Control platform gives them an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing them to identify, validate, and potential drug targets within the system.